Terence Flynn
Stock Analyst at Morgan Stanley
(4.01)
# 393
Out of 4,810 analysts
183
Total ratings
55.1%
Success rate
7.53%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OGN Organon & Co. | Maintains: Equal-Weight | $16 → $15 | $11.30 | +32.74% | 9 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,146 → $1,124 | $754.35 | +49.00% | 19 | Apr 9, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $163 → $164 | $154.36 | +6.25% | 20 | Apr 9, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $239 → $241 | $179.10 | +34.56% | 15 | Apr 9, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $328 → $330 | $293.92 | +12.28% | 6 | Apr 9, 2025 | |
| ARVN Arvinas | Maintains: Equal-Weight | $48 → $12 | $7.40 | +62.16% | 8 | Mar 13, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $145 → $139 | $102.34 | +35.82% | 2 | Mar 11, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $69 → $63 | $18.51 | +240.36% | 2 | Mar 7, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $36 → $25 | $7.68 | +225.52% | 5 | Feb 18, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Underweight | $30 → $32 | $38.81 | -17.55% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $113 → $106 | $79.17 | +33.89% | 16 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $9.85 | +72.59% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $7.50 | +46.67% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $39 | $51.34 | -24.04% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $22.12 | +40.14% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $18.95 | +522.69% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $5.39 | +567.90% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $32.29 | +57.94% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $310 → $321 | $284.31 | +12.90% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $82.53 | +103.56% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $1.23 | +550.41% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $119.26 | +265.59% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $240.01 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.30 | - | 1 | Jul 21, 2017 |
Organon & Co.
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $11.30
Upside: +32.74%
Eli Lilly and Company
Apr 9, 2025
Maintains: Overweight
Price Target: $1,146 → $1,124
Current: $754.35
Upside: +49.00%
Johnson & Johnson
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $163 → $164
Current: $154.36
Upside: +6.25%
AbbVie
Apr 9, 2025
Maintains: Overweight
Price Target: $239 → $241
Current: $179.10
Upside: +34.56%
Amgen
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $328 → $330
Current: $293.92
Upside: +12.28%
Arvinas
Mar 13, 2025
Maintains: Equal-Weight
Price Target: $48 → $12
Current: $7.40
Upside: +62.16%
BioNTech SE
Mar 11, 2025
Maintains: Overweight
Price Target: $145 → $139
Current: $102.34
Upside: +35.82%
Biohaven
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $18.51
Upside: +240.36%
Arcus Biosciences
Feb 18, 2025
Maintains: Overweight
Price Target: $36 → $25
Current: $7.68
Upside: +225.52%
CRISPR Therapeutics AG
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $38.81
Upside: -17.55%
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $79.17
Upside: +33.89%
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $9.85
Upside: +72.59%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $7.50
Upside: +46.67%
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $51.34
Upside: -24.04%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $22.12
Upside: +40.14%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $18.95
Upside: +522.69%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $5.39
Upside: +567.90%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $32.29
Upside: +57.94%
Jul 11, 2024
Downgrades: Equal-Weight
Price Target: $310 → $321
Current: $284.31
Upside: +12.90%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $82.53
Upside: +103.56%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $1.23
Upside: +550.41%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $119.26
Upside: +265.59%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $240.01
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.30
Upside: -